Treatment for ischemic stroke

A method for the improvement of function insufficiency accompanied by cerebral infarction, which comprises that a) a therapeutically effective amount of a tissue plasminogen activator as the first component and, (b) a therapeutically effective amount of [7-(1H-imidazoll-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof as the second component are administered to a patient.

A combination for the treatment of ischemic stroke, which comprises a) a therapeutically effective amount of a tissue plasminogen activator as the first component and (b) a therapeutically effective amount of [7(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof as the second component.

A combination for the treatment of ischemic stroke, which comprises a) a therapeutically effective amount of a tissue plasminogen activator as the first component with (b) a therapeutically effective amount of [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof as the second component and, in the said combination, the said first and second components are intended for different uses in the same or the successive phase or in the apart phases in terms of time.

The use of a combination of a tissue plasminogen activator with [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof for the manufacture of a medicament for the treatment of ischemic stroke.

A pharmaceutical composition for the improvement of function insufficiency accompanied by cerebral infarction, which comprises [7-(1H-imidazol-1-yl)-6-nitro2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof in a therapeutically effective amount when administered to a patient suffered from ischemic stroke and has administered a therapeutically effective amount of a tissue plasminogen activator.

The use of [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof for the manufacture of a medicament for the improvement of function insufficiency accompanied by cerebral infarction, which is administered to the patient to which a therapeutically effective amount of a tissue plasminogen activator has been administered.

A pharmaceutical composition comprising [7-(1-Himidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof in a therapeutically effective amount for potentiating the reducing effect of cerebral infarction volume by treatment a tissue plasminogen activator to a patient during the period between an onset of ischemic stroke and four hours after thereof.

The use of [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof for the manufacture of a medicament for potentiating the reducing effect of cerebral infarction volume by treatment a tissue plasminogen activator, wherein the medicament is administered to a patient during the period between an onset of ischemic stroke and four hours after thereof.

A method for improving function insufficiency accompanied by cerebral infarction, which comprises administering a therapeutically effective amount of [7-(1-Himidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof to a patient suffered from ischemic stroke and has administered a therapeutically effective amount of a tissue plasminogen activator.

A method for potentiating the reducing effect of cerebral infarction volume by treatment a tissue plasminogen activator, which comprises administering a therapeutically effective amount of [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt or hydrate thereof to a patient during the period between an onset of ischemic stroke and four hours after thereof.